Management attributed the Q4 adjusted EBITDA loss primarily to non-recurring wind-down costs of migrant-related programs, marking a definitive shift toward core healthcare services.

The acquisition of SteadyMD is a central strategic pillar, exceeding $8 million in quarterly revenue and providing a clinical network to support virtual care across all mobile offerings by Q2 2026.

Operational performance in medical transportation is improving as the company successfully filled 206 of 546 open EMT and paramedic roles, directly reducing reliance on expensive third-party outsourcing.

Strategic positioning with insurance payers is deepening, evidenced by a 12% sequential increase in assigned lives to 1.45 million and expansion into new geographic markets like Kentucky.

The ‘Efficiency Innovation Portfolio’ was launched to create operating leverage through 12+ projects focused on automating billing, dispatch, and patient outreach via AI.

Management initiated a formal process to explore strategic alternatives with an investment bank to maximize shareholder value, though outcomes remain uncertain.

High customer satisfaction, reflected in a Net Promoter Score of 92, is being maintained even as the company transitions to more automated administrative and support functions.

Revenue guidance for 2026 was increased to $290 million to $310 million, assuming continued momentum in medical transportation and SteadyMD expansions for GLP-1 programs.

Management expects to achieve adjusted EBITDA profitability in the second half of 2026, driven by a 10% to 15% reduction in SG&A and improved gross margins.

The financial framework assumes overtime rates will decline from 13% toward sub-10% levels as new clinical hires are fully integrated into the field.

Cash flow is expected to face near-term pressure due to working capital needs for new hires and operating losses, with a ‘plateauing’ expected in the back half of the year.

The company is negotiating with its credit provider to remedy financial covenant issues resulting from recent EBITDA-negative quarters to ensure continued liquidity.

Management wrote down all intangible assets and goodwill to zero, totaling $72.1 million in non-cash charges, to align carrying value with the company’s market capitalization.

A $5 million impairment was taken on a legacy equity investment in a healthcare company, which management characterized as an accounting-driven non-cash event.

A $20 million delay in collecting migrant-related accounts receivable from New York City impacted year-end cash, though management maintains these funds are ‘imminent’ following an audit completion.

Mobile health gross margins were temporarily suppressed below 20% in Q4 due to ‘stranded costs’ from the final stages of migrant program closures.